Articles: Damien Conover, CFA

Title Collection Author Date
GSK Pfizer Joint Venture No Impact on Company Value Equity Research & Insights Damien Conover, CFA 20/12/18
Novartis Deal Will Strengthen Glaxo's Dividend say Analysts Equity Research & Insights Damien Conover, CFA 28/03/18
Pfizer Offers Dividend Opportunity Equity Research & Insights Damien Conover, CFA 07/06/17
Market Outlook: Healthcare Stocks Equity Research & Insights Damien Conover, CFA 13/04/17
What Does President Trump Mean for Healthcare Stocks? Equity Research & Insights Damien Conover, CFA 10/11/16
AstraZeneca Shares Upgraded Thanks to Weak Sterling Equity Research & Insights Damien Conover, CFA 24/10/16
AstraZeneca Fairly Valued after Solid Q3 Equity Research & Insights Damien Conover, CFA 10/11/15
Pharmaceutical Stocks Get Sales Boost from Clinical Report Equity Research & Insights Damien Conover, CFA 15/05/15
Investment Focus: AstraZeneca Equity Research & Insights Damien Conover, CFA 12/05/15
AstraZeneca is Overvalued Equity Research & Insights Damien Conover, CFA 27/04/15
Is Glaxo's Dividend at Risk? Equity Research & Insights Damien Conover, CFA 05/02/15
What's in the Pipeline for AstraZeneca Equity Research & Insights Damien Conover, CFA 07/11/14
British Pharmaceutical Companies Lag Global Peers Equity Research & Insights Damien Conover, CFA 04/11/14
Astra Shares Worth £35 Equity Research & Insights Damien Conover, CFA 04/06/14
Astra Overvalues Prospects Equity Research & Insights Damien Conover, CFA 07/05/14
Analyst View: AstraZeneca Merger Equity Research & Insights Damien Conover, CFA 28/04/14
GlaxoSmithKline Undervalued, say Analysts Equity Research & Insights Damien Conover, CFA 11/12/13
GlaxoSmithKline is Undervalued, say Analysts Equity Research & Insights Damien Conover, CFA 28/10/13
AstraZeneca Undervalued, say Analysts Equity Research & Insights Damien Conover, CFA 09/10/13
GlaxoSmithKline Retains its Competitive Advantage Equity Research & Insights Damien Conover, CFA 19/08/13
AstraZeneca is "Undervalued" Say Analysts Equity Research & Insights Damien Conover, CFA 08/08/13
Boosting Big Pharma Valuations on Lower Cost of Equity Assumptions Equity Research & Insights Damien Conover, CFA 03/06/13
Improving Long-Term Outlook for Big Pharma in 2013 Equity Research & Insights Damien Conover, CFA 22/01/13
Amylin Purchase Makes Sense for AstraZeneca Equity Research & Insights Damien Conover, CFA 03/07/12
AstraZeneca and Pfizer to Lead Big Pharma M&A Premium Exclusive Damien Conover, CFA 22/03/12
Can AstraZeneca Navigate Its Pipeline Waters? Equity Research & Insights Damien Conover, CFA 06/01/12
Emerging Markets Keep Astra on Top of Patent Cliff Equity Research & Insights Damien Conover, CFA 29/07/11
New Drugs Help GSK Offset Generic Competition Equity Research & Insights Damien Conover, CFA 28/07/11
Tax Settlement Helps AstraZeneca Post In-line 1Q Equity Research & Insights Damien Conover, CFA 28/04/11
Mixed 1Q from Glaxo as Weak Sales Weigh on Growth Equity Research & Insights Damien Conover, CFA 28/04/11
AstraZeneca Positioned to Offset Patent Losses Equity Research & Insights Damien Conover, CFA 04/03/11
Can Glaxo Withstand Generic Competition? Equity Research & Insights Damien Conover, CFA 07/02/11
Glaxo's Stock Buyback Plan Signals Undervaluation Equity Research & Insights Damien Conover, CFA 03/02/11
Astra Posts Solid 4Q but Lowers Long-Term Outlook Equity Research & Insights Damien Conover, CFA 27/01/11
Still 80% Chance of Approval for Astra’s Brilinta Equity Research & Insights Damien Conover, CFA 20/12/10
AstraZeneca Likely to Hit the Top of its Guidance Equity Research & Insights Damien Conover, CFA 28/10/10
Glaxo's 3Q Earnings Hit by Avandia Charges Equity Research & Insights Damien Conover, CFA 22/10/10
Swings and Roundabouts In the Pharma Industry Equity Research & Insights Damien Conover, CFA 27/09/10
Agencies React Negatively to Avandia Equity Research & Insights Damien Conover, CFA 24/09/10
Sanofi Can Stretch Further to Secure Genzyme Equity Research & Insights Damien Conover, CFA 31/08/10
Favourable 2Q and Panel Vote for AstraZeneca Equity Research & Insights Damien Conover, CFA 29/07/10
Glaxo's 2Q Tops Expectations Equity Research & Insights Damien Conover, CFA 21/07/10
GlaxoSmithKline Can Swallow Bitter Pill Equity Research & Insights Damien Conover, CFA 16/07/10
Big Pharma Outlook for 2Q and Beyond Equity Research & Insights Damien Conover, CFA 13/07/10
Toprol and Tax Gains Buoy Astra's 1Q Equity Research & Insights Damien Conover, CFA 30/04/10
Vaccine Sales Aid GlaxoSmithKline's 1Q Equity Research & Insights Damien Conover, CFA 29/04/10
Glaxo takes steps to improve long-term prospects Equity Research & Insights Damien Conover, CFA 10/02/10
Trends so far in big pharma's fourth quarter Equity Research & Insights Damien Conover, CFA 01/02/10
AstraZeneca issues disappointing guidance Equity Research & Insights Damien Conover, CFA 28/01/10
The 2010 outlook for big pharma stocks Equity Research & Insights Damien Conover, CFA 21/01/10
Page   1 of 2

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites